Bone Morphogenetic Protein-7
human, recombinant, E. coli
For in vitro use only!
Shipping: shipped at ambient temperature
Storage Conditions: store at -20 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Molecular Weight: 16 kDa
Accession number: P18075
Accession number: P18075
Purity: > 95 % (SDS-PAGE, RP-HPLC, FPLC)
Form: lyophilised (BMP-7 was lyophilised from a 1 mg/ml solution containing 10 mM sodium citrate pH 3.5)
Solubility: It is recommended to reconstitute the lyophilised BMP-7 in sterile bidest. H2O not less than 100 μg/ml, which can then be further diluted to other aqueous solutions.
Bone morphogenetic proteins (BMPs) are key regulators of bone formation. Bone morphogenetic protein-7 (BMP7), a member of the TGFβ superfamily of cytokines, plays pivotal roles during embryogenic renal and eye development. In adults, BMP-7 expression is retained in only a few tissues, most prominently in kidney. In experimental rodent models of obstructive or diabetic nephropathy, exogenously administered BMP-7 reduces glomerular and tubulointerstitial fibrosis and preserves renal function. BMPs are synthesized as large precursor molecules which are cleaved by proteolytic enzymes. The active form can consist of a dimer of two identical proteins or a heterodimer of two related bone morphogenetic proteins. Recombinant human BMP-7 produced in E. coli is a monomeric, non-glycosylated, polypeptide chain containing 139 amino acids and having a molecular mass of 15.68 kDa. BMP-7 is purified by proprietary chromatographic techniques.
Wang et al. (2004) Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J. Biol. Chem. 279:23200.
Simon et al. (2002) Cloning of the 5'-flanking region of the murine bone morphogenetic protein-7 gene. Mol. Cell Biochem. 233:31.
Kontaxis et al. (2004) Mechanical testing of recombinant human bone morphogenetic protein-7 regenerated bone in sheep mandibles. Proc. Inst. Mech. Eng. [H] 218:381.
Roldan et al. (2004) Sinus floor augmentation with simultaneous placement of dental implants in the presence of platelet-rich plasma or recombinant human bone morphogenetic protein-7. Clin. Oral. Implants Res. 15:716.
Abu-Serriah et al. (2004) Histological assessment of bioengineered new bone in repairing osteoperiosteal mandibular defects in sheep using recombinant human bone morphogenetic protein-7. Br. J. Oral. Maxillofac. Surg. 42:410.
Li et al. (2004) Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Curr. Opin. Nephrol. Hypertens. 13:417.
Borovecki et al. (2004) Bone morphogenetic protein-7 from serum of pregnant mice is available to the fetus through placental transfer during early stages of development. Nephron. Exp. Nephrol. 97:e26.
Kawaguchi et al. (2004) Are recombinant human bone morphogenetic protein-7 and tobramycin compatible? An experiment in rats. J. Orthop. Trauma. 18:225.